Anbio Biotechnology (NNNN) FinancialsNNNNAnbio Biotechnology

Evaluating the bottom line, Anbio Biotechnology maintains a gross margin of 87.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 66.70%, while the net margin is 74.06%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively NNNN converts its operational activities into shareholder value.

In the context of the broader market, NNNN competes directly with industry leaders such as STAA and IRMD. With a market capitalization of $1.10B, it holds a significant position in the sector. When comparing efficiency, NNNN's gross margin of 87.24% stands against STAA's 74.55% and IRMD's 74.07%. Such benchmarking helps identify whether Anbio Biotechnology is trading at a premium or discount relative to its financial performance.

Anbio Biotechnology has a gross margin of 92.32% for Q2 2025, indicating strong profitability potential. The current ratio is exceptionally high at 211.10, suggesting excellent liquidity and financial health.